Li Baoli, Che Li, Li Huixian, Min Fangdi, Ai Bolun, Wu Linxin, Wang Taihang, Tan Peixin, Fu Bingbing, Yang Jiashuo, Fang Yi, Zheng Hui, Yan Tao
Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Cardiology, Central Hospital of Dalian University of Technology, Dalian, China.
Front Immunol. 2025 Jan 29;16:1531639. doi: 10.3389/fimmu.2025.1531639. eCollection 2025.
Tumor progression and chronic postsurgical pain (CPSP) in patients with breast cancer are both significantly influenced by inflammation. The associations between immunoinflammatory biomarkers and long-term survival, as well as CPSP, remain ambiguous. This study examined the predictive value of immunoinflammatory biomarkers for both long-term survival and CPSP.
Data on the clinicopathological characteristics and perioperative peripheral blood immunoinflammatory biomarkers of 80 patients who underwent breast cancer surgery were retrospectively collected. Optimal cut-off values for preoperative immunoinflammatory biomarkers, including the preoperative systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), and pan-immune-inflammation value (PIV), were established via receiver operating characteristic (ROC) curves. Kaplan-Meier curves and Cox regression analysis were used to evaluate the relationships between preoperative immunoinflammatory biomarkers and long-term survival. The relationships among the perioperative neutrophil count (NEU), monocyte count (MONO), lymphocyte count (LYM), platelet count (PLT), SII, SIRI, NLR, PIV, dynamic changes in peripheral blood cell counts, and CPSP were further assessed using logistic regression analysis.
Kaplan-Meier curves revealed a considerable prolongation of disease-free survival (DFS) and overall survival (OS) in the low preoperative SII, SIRI, NLR, and PIV groups. Multivariate Cox regression analysis revealed that only an elevated preoperative SIRI was an independent risk factor for postoperative DFS (HR=8.890, P=0.038). The incidence of CPSP was 28.75%. Univariate logistic regression analysis revealed that body mass index (BMI), postoperative NEU, MONO, SIRI, and PIV were negatively correlated with the occurrence of CPSP, whereas subsequent multivariate logistic regression analysis revealed that only BMI was independently associated with CPSP (OR=0.262, P=0.023).
Elevated preoperative SIRI was an independent risk factor for poor DFS in breast cancer patients after surgery. In contrast, perioperative immunoinflammatory biomarkers had limited potential for predicting CPSP in patients who underwent breast cancer surgery.
乳腺癌患者的肿瘤进展和慢性术后疼痛(CPSP)均受炎症的显著影响。免疫炎症生物标志物与长期生存以及CPSP之间的关联仍不明确。本研究探讨了免疫炎症生物标志物对长期生存和CPSP的预测价值。
回顾性收集80例行乳腺癌手术患者的临床病理特征及围手术期外周血免疫炎症生物标志物数据。通过受试者工作特征(ROC)曲线确定术前免疫炎症生物标志物的最佳临界值,包括术前全身免疫炎症指数(SII)、全身炎症反应指数(SIRI)、中性粒细胞与淋巴细胞比值(NLR)和全免疫炎症值(PIV)。采用Kaplan-Meier曲线和Cox回归分析评估术前免疫炎症生物标志物与长期生存的关系。使用逻辑回归分析进一步评估围手术期中性粒细胞计数(NEU)、单核细胞计数(MONO)、淋巴细胞计数(LYM)、血小板计数(PLT)、SII、SIRI、NLR、PIV、外周血细胞计数的动态变化与CPSP之间的关系。
Kaplan-Meier曲线显示,术前SII、SIRI、NLR和PIV较低的组无病生存期(DFS)和总生存期(OS)显著延长。多因素Cox回归分析显示,仅术前SIRI升高是术后DFS的独立危险因素(HR=8.890,P=0.038)。CPSP的发生率为28.75%。单因素逻辑回归分析显示,体重指数(BMI)、术后NEU、MONO、SIRI和PIV与CPSP的发生呈负相关,而随后的多因素逻辑回归分析显示,仅BMI与CPSP独立相关(OR=0.262,P=0.023)。
术前SIRI升高是乳腺癌患者术后DFS不良的独立危险因素。相比之下,围手术期免疫炎症生物标志物对行乳腺癌手术患者CPSP的预测潜力有限。